MIRM Mirum Pharmaceuticals
- 29.250
- -3.750-11.36%
- 29.410
- +0.160+0.55%
Mirum Pharmaceuticals News
Express News | Mirum Pharmaceuticals Inc : Leerink Partners Raises Target Price to $46 From $42
Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.BMO Capital
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $39 to $68
On Jun 18, major Wall Street analysts update their ratings for $Mirum Pharmaceuticals(MIRM.US)$, with price targets ranging from $39 to $68.Morgan Stanley analyst Michael Ulz maintains with a buy rati
Express News | Mirum Pharmaceuticals : Morgan Stanley Raises Target Price to $57.00 From $53.00
Express News | Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $57
Mirum Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
Mirum Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
JMP Securities Adjusts Price Target on Mirum Pharmaceuticals to $68 From $66, Maintains Market Outperform Rating
Mirum Pharmaceuticals (MIRM) has an average buy rating and a price target range of $39 to $71, according to analysts polled by Capital IQ.
Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?
Express News | Mirum Pharmaceuticals Inc : Citigroup Raises Target Price to $64 From $38
Express News | Mirum Pharmaceuticals Inc : Raymond James Raises Target Price to $71 From $60
Sector Update: Health Care Stocks Ease in Afternoon Trading
Health care stocks were declining Monday afternoon, with the NYSE Health Care Index decreasing 0.3% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB) fel
Sector Update: Health Care
Health care stocks were declining Monday afternoon, with the NYSE Health Care Index decreasing 0.3% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB) fel
Mirum Pharmaceuticals Shares Rise 21% After Positive Volixibat Trial Data
By Chris Wack Mirum Pharmaceuticals shares were up 21%, to $31.40, after the company reported positive interim results from two Phase 2b studies evaluating volixibat. The company said interim result
12 Health Care Stocks Moving In Monday's Intraday Session
GainersMustang Bio (NASDAQ:MBIO) stock moved upwards by 307.9% to $0.53 during Monday's regular session. The company's market cap stands at $14.9 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock
Mirum Pharmaceuticals Is Maintained at Outperform by Baird
Mirum Pharmaceuticals Is Maintained at Outperform by Baird
Mirum Pharmaceuticals Up Nearly 19%, on Pace for Largest Percent Increase Since December 2019 -- Data Talk
Mirum Pharmaceuticals, Inc. ( MIRM ) is currently at $30.77, up $4.85 or 18.7% --Would be highest close since Dec. 21, 2023, when it closed at $31.09 --On pace for largest percent increase since Dec
Express News | Stifel Reiterates Buy on Mirum Pharmaceuticals, Maintains $48 Price Target
Mirum Pharmaceuticals Advances After Reporting Positive Trial Results for Prospective Cholangitis Treatment
Mirum Pharmaceuticals (MIRM) rose more than 16% in Monday trading after reporting positive interim results for its volixibat drug candidate during phase 2b testing in patients experiencing inflammatio
Express News | Mirum Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $66 From $58
Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $50 From $45, Maintains Overweight Rating
Mirum Pharmaceuticals (MIRM) has an average rating of buy and price targets ranging from $31 to $66, according to analysts polled by Capital IQ. Price: 29.70, Change: +3.78, Percent Change: +14.58
Analysis
Price Target
No Data
